S
Shoichiro Horita
Researcher at Fukushima Medical University
Publications - 27
Citations - 584
Shoichiro Horita is an academic researcher from Fukushima Medical University. The author has contributed to research in topics: Receptor & G protein-coupled receptor. The author has an hindex of 10, co-authored 25 publications receiving 362 citations. Previous affiliations of Shoichiro Horita include Kyoto University.
Papers
More filters
Journal ArticleDOI
Ligand binding to human prostaglandin E receptor EP 4 at the lipid-bilayer interface
Yosuke Toyoda,Yosuke Toyoda,Kazushi Morimoto,Ryoji Suno,Shoichiro Horita,Keitaro Yamashita,Kunio Hirata,Yusuke Sekiguchi,Satoshi Yasuda,Satoshi Yasuda,Mitsunori Shiroishi,Tomoko Shimizu,Yuji Urushibata,Yuta Kajiwara,Yuta Kajiwara,Tomoaki Inazumi,Yunhon Hotta,Hidetsugu Asada,Takanori Nakane,Yuki Shiimura,Tomoya Nakagita,Kyoshiro Tsuge,Suguru Yoshida,Tomoko Kuribara,Takamitsu Hosoya,Yukihiko Sugimoto,Yukihiko Sugimoto,Norimichi Nomura,Miwa Sato,Takatsugu Hirokawa,Takatsugu Hirokawa,Masahiro Kinoshita,Takeshi Murata,Kiyoshi Takayama,Masaki Yamamoto,Shuh Narumiya,Shuh Narumiya,So Iwata,Takuya Kobayashi,Takuya Kobayashi +39 more
TL;DR: A ligand-binding site at the interface of the lipid bilayer that is unique among GPCRs is revealed, which should facilitate the design of new therapeutic drugs targeting both orthosteric and allosteric sites in this receptor family.
Journal ArticleDOI
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
TL;DR: This high-resolution structure allows the accurate mapping of the interaction including water-mediated hydrogen bonds and provides, for the first time, a coherent explanation of PD-1 antagonism by pembrolizumab, and provides new insights into the rational design of improved anti-PD-1 therapeutics.
Journal ArticleDOI
TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice.
Yuko Ono,Yuko Maejima,Masafumi Saito,Kazuho Sakamoto,Shoichiro Horita,Kenju Shimomura,Shigeaki Inoue,Joji Kotani +7 more
TL;DR: Results indicate that pharmacological inhibition of TLR4 signalling may be a novel therapeutic intervention for endotoxemia-induced muscle wasting and pretreatment with TAK-242 reduced or reversed all the detrimental effects of LPS in vitro and in vivo.
Journal ArticleDOI
Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog
Hidetsugu Asada,Shoichiro Horita,Kunio Hirata,Mitsunori Shiroishi,Yuki Shiimura,Hiroko Iwanari,Takao Hamakubo,Tatsuro Shimamura,Norimichi Nomura,Osamu Kusano-Arai,Tomoko Uemura,Chiyo Suno,Takuya Kobayashi,Takuya Kobayashi,So Iwata +14 more
TL;DR: The crystal structure of human AT2R binding an angiotensin II analog reveals ‘core’ and ‘extended’ domains within the binding pocket, and a signature positively charged motif orients the C terminus of the peptide ligand at the bottom of the bindingpocket.
Journal ArticleDOI
A mutation in transcription factor MAFB causes Focal Segmental Glomerulosclerosis with Duane Retraction Syndrome.
Yoshinori Sato,Hiroyasu Tsukaguchi,Hiroyuki Morita,Koichiro Higasa,Mai Thi Nhu Tran,Michito Hamada,Toshiaki Usui,Naoki Morito,Shoichiro Horita,Takao Hayashi,Junko Takagi,Izumi Yamaguchi,Huan Thanh Nguyen,Masayo Harada,Kiyoko Inui,Yuichi Maruta,Yoshihiko Inoue,Fumihiko Koiwa,Hiroshi Sato,Fumihiko Matsuda,Shinya Ayabe,Seiya Mizuno,Fumihiro Sugiyama,Satoru Takahashi,Ashio Yoshimura +24 more
TL;DR: Two unrelated families with FSGS associated with Duane Retraction Syndrome were studied, revealing that affected individuals harbor a rare heterozygous substitution in MAFB, a leucine zipper transcription factor that impair development and/or maintenance of podocytes, abducens neurons and the inner ear.